About the Company
We do not have any company description for BRAINSTORM CELL THERAPEUTICS INC. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 14, 2025Brainstorm Cell Therapeutics Inc. beats earnings expectations.
Brainstorm Cell Therapeutics outlines readiness for Phase IIIb ALS trial as funding and regulatory developments shape next steps
Q2 2025 Management View Chaim Lebovits, President and CEO, reaffirmed that "our top priority is advancing NurOwn into our planned Phase IIIb clinical trial." The ENDURANCE trial is designed to confirm ...
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial ...
NEW YORK, May 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics ...
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and ...
BrainStorm Cell Therapeutics Inc. (BCLI) is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
BrainStorm Cell Therapeutics Presented Positive Survival Data from ...
--BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of two posters featuring NurOwn ® at the 2024 ...
BrainStorm Cell Therapeutics and Pluri Partner to Support ... - Nasdaq
--BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding with Pluri Inc ...
BrainStorm Cell Therapeutics Reports Q2 2025 Progress
Brainstorm Cell Therapeutics ( ($BCLI) ) has released its Q2 earnings. Here is a breakdown of the information Brainstorm Cell Therapeutics ...
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call ...
Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.49 EPS, expectations were $-0.49. Operator: Good morning, everyone, and welcome to BrainStorm Cell ...
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn ...
By BrainStorm Cell Therapeutics Inc. Nov 11, 2024 Nov 11, 2024Updated Nov 11, 2024 BrainStorm Logo By BrainStorm Cell Therapeutics Inc. Memorandum of Understanding has been signed ...
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial ...
NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced ...
Similar Companies
Loading the latest forecasts...